[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Hospital Universitari Vall d'Hebron Research Institute\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":728},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,49,0,25,[9,46,73,114,144,172,208,237,260,284,315,339,376,398,429,455,481,519,544,567,595,618,653,676,708],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100644093","phase-3-optimizing-the-use-of-aspirin-for-the-prevention-of-preeclampsia-100644093",false,"NCT07665853","Optimizing the Use of Aspirin for the Prevention of Preeclampsia","Optim-PRE","Inclusion Criteria:\n\n* Age 18 years or older at time of enrollment.\n* Singleton pregnancy.\n* Ability to read and understand the informed consent form.\n* Having undergone first-trimester preeclampsia screening between 11+0 and 13+6 weeks of gestation using a validated multiparametric algorithm (FMF algorithm at a risk cutoff of 1:100, or Gaussian algorithm at a cutoff of 1:170) and being classified as high risk for preterm preeclampsia.\n* Currently taking aspirin 150 mg\u002Fday initiated after first-trimester high-risk classification, in accordance with standard clinical practice.\n* Voluntary signing of the informed consent form and willingness to comply with the study requirements, including acceptance of the assigned aspirin treatment duration, additional blood tests, and additional ultrasound assessments.\n\nExclusion Criteria:\n\n* Early pregnancy loss, intrauterine fetal death, or fetus with major structural malformations diagnosed at the time of enrollment.\n* Fetus affected by a known genetic or chromosomal disease.\n* Contraindication, allergy, or intolerance to aspirin (acetylsalicylic acid).\n* Any medical condition that makes aspirin discontinuation unsafe or impossible (e.g., antiphospholipid syndrome, mechanical heart valve, or other conditions requiring indefinite antiplatelet or anticoagulant therapy).","FEMALE","18 Years",{"count":20,"type":21},15160,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","Pregnant women at higher risk for preeclampsia (PE) are currently recommended to take low-dose aspirin (acetylsalicylic acid, ASA) daily from the first trimester until 36 weeks of gestation. High-risk women are identified through a multiparametric first-trimester screening that combines maternal history, blood pressure, uterine artery blood flow, and placental growth factor (PlGF). Although this screening effectively identifies women at risk, the majority of those classified as high risk will not develop PE. As a result, a large proportion of pregnant women receive prolonged aspirin treatment without benefit, while remaining exposed to its potential side effects, including increased bleeding risk.\n\nAspirin prevents PE primarily by improving placental development during the first half of pregnancy. Whether continuing ASA beyond 24-28 weeks provides additional protection remains unclear. A previous randomized trial demonstrated that stopping ASA at 24-28 weeks was non-inferior to continuing until 36 weeks in a predominantly European population. However, whether this finding applies to more diverse populations, including women of African origin who carry a substantially higher baseline risk of PE, has not been established.\n\nThis is a multicenter, randomized, open-label, parallel-group, phase III non-inferiority trial conducted across sites in Europe and Africa. A total of 15,160 pregnant women at high risk for PE from first-trimester screening, currently under ASA treatment, will be randomized in a 1:1 ratio before 28 weeks of gestation to either discontinue ASA at 24-28 weeks or continue ASA until 36 weeks of gestation.",[27],"Preeclampsia",[27,29,30,31,32],"First Trimester Screening","Placental Growth Factor","Ophthalmic Artery Doppler","Acetyl Salicylic Acid (ASA)","NOT_YET_RECRUITING","2026-06-18",{"date":36,"type":37},"2026-06-24","ACTUAL",{"date":39,"type":21},"2026-07-01",{"date":41,"type":21},"2028-05",{"name":43,"class":44},"Hospital Universitari Vall d'Hebron Research Institute","OTHER",38,{"id":47,"slug":48,"hasResults":12,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":12,"sex":53,"minAge":18,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},"100537070","treatment-of-fecal-incontinence-and-functional-evacuation-disorders-using-non-instrumental-biofeedback-100537070","NCT06273046","Treatment of Fecal Incontinence and Functional Evacuation Disorders Using Non-instrumental Biofeedback","Tratamiento de la Incontinencia Fecal y Los Trastornos Funcionales de la defecación Mediante Biofeedback no Instrumental","Inclusion Criteria:\n\nIncontinence studies\n\n* Patients who have at least 4 episodes of fecal incontinence during the last 14 days.\n* Patients able to follow instructions and attend study visits.\n\nDyssinergic defecation studies\n\n* Patients with constipation who present less than 3 complete spontaneous bowel movements per week and\u002For who have Bristol 1 or Bristol 2 type stools in more than 25% of the bowel movements in the 2 weeks prior to the study\n* Patients able to follow instructions and attend study visits.\n\nExclusion Criteria:\n\n* Patients with organic digestive diseases such as inflammatory bowel disease, celiac disease, gastro-duodenal ulcer...\n* Patients with neurological diseases (spinal cord injury, multiple sclerosis, Parkinson's disease).\n* Patients with previous of active colon and\u002For rectal cancer.\n* Patients with rectal fistula.\n* Patients with rectal prolapse.\n* Patients with total colectomy.\n* Patients who have had any radiation to the pelvis in the last month.","ALL","75 Years",{"count":56,"type":21},96,[58],"NA","Background. Rehabilitation and re-education using instrumental anorectal biofeedback are the main treatment of anorectal functional disorders producing incontinence and outlet obstructed defecation. These treatments imply intubation of patient and several sessions of treatment leading to high consumption of resources and costs.\n\nHypothesis. A cognitive intervention based on original audiovisual programs developed specifically for the management of anorectal functional disorders is effective in correcting anorectal function disorders that cause fecal incontinence and evacuation disorders.\n\nAim. To prove in two different protocols (fecal incontinence and dyssinergic defecation) the efficacy of specifically developed non-instrumental biofeedback techniques.\n\nSelection criteria. Patients with fecal incontinence and altered sphincter function and patients with outlet obstructed evacuation referred for biofeedback treatment.\n\nIntervention. In separate studies (incontinence and dyssynergic defecation) patients will be randomized into biofeedback and placebo groups. One session of either biofeedback or placebo intervention will be performed at the beginning of the intervention period and patients will be instructed to performed the assigned daily treatment at home. A visit for outcome assessment will be performed at 3 months in incontinence study and at 4 weeks in the dyssinergic defecation study. In addition, in the incontinence study a phone call will be performed after 6 months of the beginning of the study to evaluate treatment outcome.\n\nBiofeedback: patients will be taught to control anal and abdominal muscular activity by providing instructions using original video supports. Patients will be instructed to perform the same exercises daily at home in scheduled times.\n\nPlacebo: a pill of placebo containing 0.3 g glucose will be administered every day at home.",[61,62],"Fecal Incontinence","Outlet Dysfunction Constipation","RECRUITING","2026-06-11",{"date":66,"type":37},"2026-06-15",{"date":68,"type":37},"2024-04-17",{"date":70,"type":21},"2026-08-30",{"name":43,"class":44},1,{"id":74,"slug":75,"hasResults":12,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":12,"sex":53,"minAge":18,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":87,"conditions":88,"keywords":95,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":72},"100640982","phase-1-immunological-reset-to-enable-access-to-hla-compatible-kidney-transplantation-in-highly-sensitized-patients-reset-100640982","NCT07607197","Immunological Reset to Enable Access to Hla-compatible Kidney Transplantation in Highly Sensitized Patients (RESET)","Immune Reset to Allow Access to Hla-compatible Kidney Transplantation in Hyperimmunized Patients","HIPER-RESET","Inclusion Criteria:\n\n* Patients aged between 18 and 60 years.\n* Diagnosis of end-stage kidney disease (ESRD) currently maintained on chronic dialysis.\n* Highly sensitized\u002Fhyperimmunized status, defined by a high calculated Panel Reactive Antibody (cPRA) level (e.g., \\>= 95%).\n* Active status on the deceased-donor kidney transplant waiting list.\n* Adequate bone marrow, hepatic, cardiac, and pulmonary function to safely undergo the conditioning regimen and AHSCT.\n* Capable of understanding the study requirements and providing written informed consent.\n\nExclusion Criteria:\n\n* Contraindications to the conditioning regimen medications (rituximab, cyclophosphamide, or rATG).\n* Active, uncontrolled systemic infection, or chronic active infection (including HIV, active Hepatitis B or C, or active tuberculosis).\n* Significant cardiac dysfunction (e.g., Left Ventricular Ejection Fraction \\\u003C 50%) or severe underlying pulmonary disease.\n* History of malignant neoplasm within the past 5 years, excluding successfully treated non-melanoma skin cancer or carcinoma in situ.\n* Previous autologous or allogeneic hematopoietic stem cell transplantation.\n* Pregnancy or breastfeeding.\n* Any psychiatric, medical, or geographical condition that, in the investigator's opinion, prevents compliance with the protocol and long-term follow-up.","60 Years",{"count":83,"type":21},10,[85,86],"PHASE1","PHASE2","The purpose of this clinical trial is to evaluate whether a temporary reprogramming of the immune system can help highly sensitized (hyperimmunized) patients with end-stage kidney disease safely receive a compatible kidney transplant.\n\nPatients who are highly sensitized have developed an extremely high level of antibodies against human leukocyte antigens (HLA), often due to previous transplants, pregnancies, or blood transfusions. This condition makes it nearly impossible for them to find a compatible organ donor, leaving them stuck on dialysis indefinitely.\n\nThis study tests an innovative strategy using Autologous Hematopoietic Stem Cell Transplantation (AHSCT). The procedure involves an intensive conditioning regimen using a combination of medications (cyclophosphamide, thymoglobulin, and rituximab) to deeply clear out the patient's existing mature immune cells. This is followed by the reinfusion of the patient's own previously collected and purified blood stem cells (CD34+ cells) to rebuild the immune system from scratch.\n\nThe investigators hypothesize that this procedure will eliminate the \"immunological memory\" cells responsible for producing the problematic anti-HLA antibodies, resetting the immune system to a \"naive\" or inactive state. This immune reset is expected to eliminate or significantly lower circulating HLA antibodies, creating a critical window of opportunity for these patients to successfully receive a compatible kidney transplant from the deceased-donor waiting list.",[89,90,91,92,93,94],"Kidney Failure, Chronic","Kidney Transplantation","Alloimmunization","HLA Sensitization","End Stage Cronic Kidney Disease","Highly Sensitized Patients Awaiting Kidney Transplant",[96,97,90,98,99,100,101,102,103,104,105],"Autologous Hematopoietic Stem Cell Transplantation","AHSCT","Highly sensitized","Hyperimmunized","Desensitization","Anti-HLA Antibodies","CD34+ Cells","Transplant Immunology","End-Stage Kidney Disease","Immune Reset","2026-06-02",{"date":108,"type":37},"2026-06-04",{"date":110,"type":37},"2024-02-01",{"date":112,"type":21},"2028-06",{"name":43,"class":44},{"id":115,"slug":116,"hasResults":12,"nctId":117,"briefTitle":118,"officialTitle":118,"acronym":4,"eligibilityCriteria":119,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":120,"enrollmentInfo":121,"targetDuration":123,"studyType":124,"phases":4,"briefSummary":125,"conditions":126,"keywords":130,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":143},"100638472","urinary-continence-after-vaginal-surgery-for-genital-prolapse-in-the-spanish-population-100638472","NCT07628036","Urinary Continence After Vaginal Surgery for Genital Prolapse in the Spanish Population.","Inclusion Criteria:\n\n* Women who will undergo vaginal surgery for pelvic organ prolapse\n\nExclusion Criteria:\n\n* inhability to give consent to the study","99 Years",{"count":122,"type":21},1042,"1 Year","OBSERVATIONAL","Surgical correction of pelvic organ prolapse (POP) may be associated with the development of postoperative stress urinary incontinence (SUI). This clearly affects women's satisfaction and their quality of life, and may require subsequent medical and\u002For surgical treatments.\n\nOn the other hand, pre-existing SUI could resolve after corrective prolapse surgery. Similarly, urge urinary incontinence (UUI) could appear or improve after vaginal POP surgery. Therefore, it is of paramount importance to know the prevalence of urinary incontinence after POP vaginal surgery and incontinence resolution in our population. Identifying the risk factors for the development of urinary incontinence may allow to provide individualized treatment.",[127,128,129],"Pelvic Organ Prolapse (POP)","Pelvic Organ Prolapse Vaginal Surgery","Urinary Incontinence (UI)",[131,132,133,134,135],"Pelvic organ prolapse","Vaginal surgery","Urinary incontinence","Stress urinary incontinence","Urge-urinary incontinence","2026-06-01",{"date":108,"type":37},{"date":139,"type":21},"2026-08-01",{"date":141,"type":21},"2028-05-30",{"name":43,"class":44},4,{"id":145,"slug":146,"hasResults":12,"nctId":147,"briefTitle":148,"officialTitle":148,"acronym":149,"eligibilityCriteria":150,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":151,"targetDuration":4,"studyType":22,"phases":153,"briefSummary":154,"conditions":155,"keywords":157,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":171},"100623297","physical-activity-and-pregnant-women-at-increased-social-risk-a-feasibility-study-100623297","NCT07394803","Physical Activity and Pregnant Women at Increased Social Risk: a Feasibility Study","ACTIVA","Inclusion Criteria:\n\n* Maternal age above 18 years old.\n* Antenatal care at ASSIR Barcelona Nord (SAP Muntanya), and\u002For Hospital Vall d´Hebron.\n* Fulfilling social risk criteria defined by the Local Protocol (13), that includes as vulnerable socioeconomical conditions: low economic income, unemployed, poor nutrition, low educational level, difficult access to perinatal healthcare and lack of social and familiar support.\n\nExclusion Criteria:\n\n* Contraindications for the practice of physical activity during pregnancy according to the Spanish and\u002For Canadian (5,6,14)guidelines of physical activity during pregnancy (ref).\n* Unable to communicate in the official language (Spanish or Catalan)\n* Aiming to give birth in a different setting of the study setting.",{"count":152,"type":21},60,[58],"Objective: To test the feasibility of the implementation of a moderate intensity physical activity program during pregnancy in a group of pregnant women at social risk.\n\nMethods: a non-randomized feasibility study piloting several components of the trial Inclusion criteria: \\> 18 yo, antenatal care at HVH and\u002For ASSIR SAP Muntanya, and vulnerable socioeconomical conditions.\n\nExclusion criteria: contraindications for the practice of physical activity during pregnancy according to Spanish and Canadian Guidelines.\n\nPractical Course of the research: Women will be recruited for the study and will perform a physical activity moderate intensity hybrid (on-site and online) program during pregnancy (3 times per week 60 min sessions) and will respond to several questionnaires (Barriers, IPAQ, WHO-5, EPDS, STAI, SF-12, MOSSS, PSQI) Those who reject to participate in the program, will be offered to respond to these questionnaires. Main outcomes are the acceptability to the program, the reasons for rejection, the physical activity level during pregnancy, the barriers and facilitators to physical activity during pregnancy.\n\nNumber of recruiting centers: Hospital Vall d´Hebron and Primary Care Center ASSIR Muntanya (Centro de atención a la salud sexual y Reproductiva) Barcelona Nord.\n\nSample size: 60 aiming to achieve 30 women in the physical activity program\n\nStatistical analyses: quantitative descriptive analysis.\n\nSource of funding: no funding available, pending for funding",[156],"Pregnancy",[158,159,160,161,162],"physical activity during pregnancy","social risk","mental health","moderate physical activity","Facilities and barriers for physical activity in pregnant women","2026-05-19",{"date":165,"type":37},"2026-05-22",{"date":167,"type":37},"2026-02-01",{"date":169,"type":21},"2027-01-01",{"name":43,"class":44},2,{"id":173,"slug":174,"hasResults":12,"nctId":175,"briefTitle":176,"officialTitle":177,"acronym":178,"eligibilityCriteria":179,"healthyVolunteers":12,"sex":53,"minAge":4,"maxAge":18,"enrollmentInfo":180,"targetDuration":4,"studyType":22,"phases":182,"briefSummary":184,"conditions":185,"keywords":191,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":205,"leadSponsor":207,"locationsCount":143},"100639005","phase-4-early-discontinuation-of-antibiotics-in-paediatric-high-risk-febrile-neutropenia-100639005","NCT07590648","Early Discontinuation of Antibiotics in Paediatric High-risk Febrile Neutropenia","Phase IV, Randomized, Open Label, Parallel Groups Clinical Trial for Evaluating the Early Stop of Antibiotic Treatment in High-risk Febrile Neutropenic Oncohaematological Paediatric Patients (e-STOP 2)","E-STOP2","Inclusion Criteria:\n\n1. Male and female patients ≤18 years of age expected to develop prolonged neutropenia (\\>7 days), with:\n\n   * Acute myeloblastic leukaemia at any phase of chemotherapy\n   * Acute lymphoblastic leukaemia in induction, consolidation, or intensification phases\n   * Biphenotypic leukaemia at any phase of chemotherapy\n   * Lymphoblastic lymphoma in induction and consolidation phases\n   * B-cell and anaplastic lymphoma receiving high-intensity chemotherapy\n   * Solid tumours receiving high-intensity chemotherapy\n   * Relapsed leukaemia at any phase of treatment\n2. Episode of febrile neutropenia (FN), defined as a single axillary temperature ≥38.0°C in a patient with an absolute neutrophil count (ANC) \\\u003C500 neutrophils\u002Fmm³, or expected to fall below this value within the next 48-72 hours.\n3. Antibiotic treatment initiated for the current FN episode (routine antimicrobial prophylaxis is allowed, as well as teicoplanin 3 days\u002Fweek for patients with AML included in the CHIP-AML-2022 protocol and therefore in the Pro-teico study).\n4. Low risk of invasive bacterial infection (IBI) at the start of the FN episode. Patients must meet all of the following:\n\n   * CRP \\\u003C9 mg\u002FdL\n   * PCT \\\u003C0.5 ng\u002FmL\n   * Absence of hypotension\n5. No microbiologically documented bacterial infection 48-72 hours after the FN episode.\n6. Good clinical evolution 48-72 hours after the FN episode, defined as:\n\n   * Afebrile for \\>48 hours (axillary temperature \\\u003C38°C)\n   * Haemodynamically stable\n   * Stable paediatric early warning score (PEWS)\n7. CRP \\\u003C5 mg\u002FdL, or CRP \\\u003C9 mg\u002FdL and PCT \\\u003C0.5 ng\u002FmL, with decreasing trend at the time of randomisation (values will be assessed on day 3 and day 5 after the FN episode).\n8. ANC \\\u003C500 neutrophils\u002Fmm³ at the time of randomisation.\n9. Signed informed consent from the patient and\u002For parent(s)\u002Flegal representative(s).\n10. Patient and\u002For parent(s)\u002Flegal representative(s) must have sufficient reading and writing skills to understand and provide consent to participate in the study.\n11. Patient and\u002For parent(s)\u002Flegal representative(s) must be considered reliable and capable of adhering to the protocol.\n\nExclusion Criteria:\n\n1. Antibiotic treatment at the time of the FN episode different from that used prophylactically.\n2. Empirical antibiotic treatment different from that recommended in international guidelines.\n3. Patient with poor clinical evolution during the first 12 hours (hemodynamic instability, PICU admission, death).\n4. Active participation in the same study at the onset of the current FN episode.\n5. Active participation in another clinical trial that, in the investigators' opinion, may interfere with the assessment of the results.\n6. Any condition which, in the investigator's opinion, makes study participation unsuitable for the patient or could limit, prevent, or confound the assessments planned in the protocol.\n7. Female patients who are pregnant or breastfeeding",{"count":181,"type":21},136,[183],"PHASE4","The goal of this clinical trial is to evaluate whether stopping antibiotic treatment early is safe in paediatric patients with cancer who develop high-risk febrile neutropenia but show good clinical evolution and low biomarker levels 48-72 hours after the episode.\n\nThe main questions it aims to answer are:\n\nIs early discontinuation of antibiotics as safe as the standard strategy in terms of preventing invasive bacterial infections (such as sepsis, microbiologically documented infection, ICU admission, or death)? Does this strategy reduce the number of days on antibiotics without increasing infection-related complications?\n\nResearchers will compare early antibiotic discontinuation with the standard care strategy to see whether the early-stop approach provides similar safety while reducing antibiotic exposure.\n\nParticipants will:\n\nReceive standard initial antibiotic therapy for febrile neutropenia. Undergo clinical and biomarker evaluations (including CRP and PCT).\n\nBe randomly assigned to:\n\nExperimental group: early discontinuation of antibiotics, or Control group: continuation of the standard antibiotic strategy.\n\nBe followed for 28 days after randomisation to monitor safety outcomes and treatment effects.",[186,187,188,189,190],"Febrile Neutropenia (FN)","Pediatric Cancer","Hematologic Malignancies","Solid Tumors","Invasive Bacterial Infection",[192,193,188,189,190,194,195,196,197,198,199,200],"Febrile Neutropenia","Pediatric Oncology","Antibiotic Discontinuation","Antibiotic Stewardship","Biomarkers (CRP, PCT, IL-8)","Early Stop Strategy","Randomized Clinical Trial","Non-Inferiority Trial","Neutropenia","2026-05-13",{"date":203,"type":37},"2026-05-15",{"date":136,"type":21},{"date":206,"type":21},"2028-07-01",{"name":43,"class":44},{"id":209,"slug":210,"hasResults":12,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":214,"eligibilityCriteria":215,"healthyVolunteers":12,"sex":53,"minAge":18,"maxAge":4,"enrollmentInfo":216,"targetDuration":4,"studyType":124,"phases":4,"briefSummary":218,"conditions":219,"keywords":221,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":236,"locationsCount":72},"100632119","hemodynamic-and-respiratory-instability-during-percutaneous-pulmonary-thrombectomy-100632119","NCT07509541","Hemodynamic and Respiratory Instability During Percutaneous Pulmonary Thrombectomy","Hemodynamic and Respiratory Instability During Percutaneous Pulmonary Thrombectomy in Pulmonary Embolism: Mechanisms, Timing, and Clinical Impact","INSTAB-PE","Inclusion Criteria:\n\n* Patients (aged ≥18 years) with high-risk or intermediate-high-risk pulmonary embolism\n* Patients undergoing percutaneous pulmonary thrombectomy as part of routine clinical care\n\nExclusion Criteria:\n\n* Age \\\u003C18 years\n* Low-risk pulmonary embolism\n* Patients not undergoing percutaneous pulmonary thrombectomy\n* Patients presenting with refractory shock upon arrival to the interventional suite",{"count":217,"type":21},100,"Pulmonary embolism (PE) is a potentially life-threatening condition caused by the obstruction of pulmonary arteries by thrombi. Patients with high-risk or intermediate-high-risk PE may require immediate reperfusion therapies, including percutaneous pulmonary thrombectomy. However, this procedure can be associated with significant hemodynamic and respiratory instability, potentially leading to shock, cardiac arrest, or the need for advanced support such as mechanical ventilation or extracorporeal membrane oxygenation (ECMO).\n\nThe mechanisms, timing, and causes of intraprocedural hemodynamic and respiratory deterioration during pulmonary thrombectomy are not well established. Factors such as catheter manipulation within the pulmonary arteries, increased pulmonary pressures, and the effects of anesthesia and mechanical ventilation may contribute to clinical instability. In addition, biomarkers such as NT-proBNP may reflect right ventricular strain and could help predict the risk of instability during the procedure.\n\nThe aim of this prospective observational study is to determine the incidence, causes, and timing of hemodynamic and\u002For respiratory instability during percutaneous pulmonary thrombectomy in patients with high-risk or intermediate-high-risk PE. The study will also compare the occurrence of instability between different thrombectomy devices (FlowTriever® and Indigo® systems) and evaluate the prognostic role of baseline NT-proBNP levels. Secondary objectives include the assessment of in-hospital and 30-day mortality and their underlying causes.\n\nThis study will include adult patients undergoing percutaneous pulmonary thrombectomy as part of routine clinical care. The results of this study may help improve risk stratification, guide procedural planning, and optimize the management of patients undergoing pulmonary thrombectomy, ultimately aiming to reduce morbidity and mortality.",[220],"Pulmonary Embolism Acute",[222,223,224,225,226,227,228],"Pulmonary Embolism","Percutaneous Pulmonary Thrombectomy","Catheter-Directed Thrombectomy","Hemodynamic Instability","Respiratory Instability","Shock","NT-proBNP","2026-04-28",{"date":231,"type":37},"2026-05-04",{"date":233,"type":21},"2026-04-10",{"date":235,"type":21},"2030-05-10",{"name":43,"class":44},{"id":238,"slug":239,"hasResults":12,"nctId":240,"briefTitle":241,"officialTitle":242,"acronym":243,"eligibilityCriteria":244,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":245,"targetDuration":4,"studyType":124,"phases":4,"briefSummary":247,"conditions":248,"keywords":251,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":256,"completionDateStruct":257,"leadSponsor":259,"locationsCount":72},"100632873","migraine-and-endometriosis-the-feminine-study-100632873","NCT07519343","Migraine and Endometriosis: The FEMININE Study","Investigating the inFluence of EndoMetriosis IN migraINE - FEMININE Study","FEMININE","Inclusion Criteria:\n\n1. Adult females (≥18 years old).\n2. Diagnosis of migraine according to ICHD-3 criteria confirmed by a headache specialist (for MIG-O and MIG-EDM groups).\n3. Confirmed diagnosis of endometriosis based on clinical symptoms and imaging or surgical criteria according to ESHRE guidelines (for EDM-O and MIG-EDM groups).\n4. Signed informed consent.\n\nExclusion Criteria:\n\n1. Individuals diagnosed with secondary headache according to the ICHD-3.\n2. Individuals with a severe disease (e.g., major psychiatric disorder, severe cardiovascular conditions).\n3. History of, treatment for, or evidence of, alcohol or drug abuse within the past 12 months.\n4. Pregnant or breastfeeding females.",{"count":246,"type":21},150,"Migraine and endometriosis are common conditions that mainly affect females of reproductive age. Both can cause significant pain and have a strong impact on the quality of life. Increasing evidence suggests that these two conditions often occur together, and that females who have both may experience more severe symptoms than those with only one of them. However, the reasons why migraine and endometriosis are linked are still not well understood.\n\nSome biological factors may help explain this connection. One of them is a molecule called calcitonin gene-related peptide (CGRP), which plays an important role in migraine and may also be involved in pain and inflammation in endometriosis. In addition, hormonal changes during the menstrual cycle, especially fluctuations in estrogen levels, may influence symptoms in both conditions. Genetic and epigenetic factors may also contribute to this association.\n\nThe main hypothesis of this study is that females who have both migraine and endometriosis have a distinct clinical and biological profile compared to females who have only migraine or only endometriosis. In particular, it is expected that differences will be observed in CGRP levels and hormonal patterns across the menstrual cycle.\n\nThe FEMININE study is a prospective observational study that will follow females over several menstrual cycles. It will include three groups: females with both migraine and endometriosis, females with migraine only, and females with endometriosis only. Participants will record their symptoms in diaries and will provide blood samples at specific times of the menstrual cycle.\n\nThe main goal of the study is to compare CGRP levels between groups. Additional goals include describing differences in symptoms, menstrual-related migraine, hormonal levels, and selected genetic and epigenetic markers.\n\nBy improving the understanding of how migraine and endometriosis are related, this study aims to support better diagnosis and more personalized care for females affected by these conditions.",[249,250],"Migraine","Endometriosis",[252],"CGRP","2026-04-02",{"date":255,"type":37},"2026-04-09",{"date":136,"type":21},{"date":258,"type":21},"2028-06-01",{"name":43,"class":44},{"id":261,"slug":262,"hasResults":12,"nctId":263,"briefTitle":264,"officialTitle":264,"acronym":4,"eligibilityCriteria":265,"healthyVolunteers":12,"sex":53,"minAge":18,"maxAge":4,"enrollmentInfo":266,"targetDuration":268,"studyType":124,"phases":4,"briefSummary":269,"conditions":270,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":277,"startDateStruct":279,"completionDateStruct":281,"leadSponsor":283,"locationsCount":4},"100632209","value-of-the-time-weighted-average-twa-of-mean-arterial-pressure-map-and-cerebral-oximetry-rso-as-predictors-of-postoperative-tissue-perfusion-impairment-in-patients-undergoing-cardiac-surgery-100632209","NCT07510711","Value of the Time-Weighted Average (TWA) of Mean Arterial Pressure (MAP) and Cerebral Oximetry (rSO₂) as Predictors of Postoperative Tissue Perfusion Impairment in Patients Undergoing Cardiac Surgery","Inclusion Criteria:\n\n* Age \\>18 years\n* Undergoing cardiac surgery, with or without cardiopulmonary bypass\n* Written informed consent\n* Preoperative cognitive status: Glasgow Coma Scale score of 15; no history of dementia; no evidence of cognitive impairment on baseline assessment; patient oriented and cooperative prior to surgery\n* Continuous intraoperative monitoring of mean arterial pressure (MAP) and cerebral regional oxygen saturation (rSO₂)\n\nExclusion Criteria:\n\n* History of dementia or cognitive impairment\n* Emergency surgeries",{"count":267,"type":21},120,"3 Months","Neurological problems after heart surgery are common and include confusion, memory loss, and difficulty thinking clearly. These issues may appear hours or days after surgery and can negatively affect recovery.\n\nDuring heart surgery, blood flow and oxygen delivery to the brain may decrease, causing changes in blood pressure and cerebral oxygenation. Previous studies suggest that prolonged drops in mean arterial pressure (MAP) or cerebral oxygenation (rSO₂) are linked to worse postoperative outcomes. Continuous monitoring of blood pressure and cerebral oxygenation is standard in cardiac surgery.\n\nThis study aims to evaluate the duration and severity of intraoperative drops in MAP and cerebral oxygenation. These measures may provide a more accurate assessment of neurological risk than isolated measurements.\n\nThe primary objective is to determine whether decreases in MAP and cerebral oxygenation, as well as their duration and intensity during surgery, are associated with postoperative neurological complications.\n\nThis is a prospective, observational study in adult patients undergoing cardiac surgery, with or without cardiopulmonary bypass (CPB). CPB diverts blood through a machine that performs the work of the heart and lungs while the heart is operated on. All patients will receive standard monitoring, including continuous MAP and cerebral oxygenation measurements. No additional interventions will be performed.\n\nNeurological status will be assessed using validated clinical scales before and after surgery. Other outcomes include kidney function, ICU and hospital stay length, postoperative complications, and in-hospital mortality.\n\nValidating these measures as a predictive tool could enable early identification of patients at higher risk of neurological injury and allow more individualized intraoperative management to reduce morbidity, hospital stay, and healthcare costs.",[271,272,273,274,275],"Delirium - Postoperative","Postoperative Cognitive Dysfunction (POCD)","Postoperative Acute Kidney Injury","Postoperative Morbidity","Intensity Care Unit Length of Stay","2026-03-30",{"date":278,"type":37},"2026-04-03",{"date":280,"type":21},"2026-05-01",{"date":282,"type":21},"2027-11",{"name":43,"class":44},{"id":285,"slug":286,"hasResults":12,"nctId":287,"briefTitle":288,"officialTitle":289,"acronym":290,"eligibilityCriteria":291,"healthyVolunteers":12,"sex":53,"minAge":292,"maxAge":4,"enrollmentInfo":293,"targetDuration":268,"studyType":124,"phases":4,"briefSummary":295,"conditions":296,"keywords":300,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":307,"lastUpdatePostDateStruct":308,"startDateStruct":310,"completionDateStruct":312,"leadSponsor":314,"locationsCount":143},"100631828","postoperative-recovery-in-elderly-patients-assessed-with-qor-15e-100631828","NCT07505758","Postoperative Recovery in Elderly Patients Assessed With QoR-15E","Postoperative Quality of Recovery in Elderly Patients Undergoing Elective Surgery With Hospital Admission: a Multicenter Prospective Cohort Study Based on Patient-reported Outcome Measures (PQoRE Study)","PQoRE","Inclusion Criteria:\n\n* Patients aged 80 years or older.\n* Undergoing elective surgery requiring hospital admission.\n* Able to understand and provide written informed consent.\n\nExclusion Criteria:\n\n* Inability to speak Spanish.\n* Pre-existing cognitive impairment.\n* Emergency or urgent surgery.\n* Neurosurgical or cardiac surgical procedures.\n* Ambulatory (outpatient) surgery without hospital admission.","80 Years",{"count":294,"type":21},600,"Postoperative recovery in elderly patients is an important part of the surgical process and affects how patients feel after surgery. To date, recovery has been measured mostly with clinical outcomes, such as complications or length of stay, but not from the patient's perspective. The QoR-15 questionnaire was designed to assess recovery from the patient's point of view and has recently been validated in Spanish as the QoR-15E.\n\nThis study aims to evaluate postoperative recovery in patients aged 80 years and older undergoing elective surgery with hospital admission, using the QoR-15E questionnaire. Patients will complete the questionnaire before surgery and on postoperative days 1, 2, 7, and 30. Additional assessments will include frailty and delirium scales, and postoperative complications will be recorded. Mortality will be evaluated 90 days after surgery, alongside the patient's subjective perception of their recovery.",[297,298,299],"Postoperative Recovery in Elderly Patients","Quality of Recovery After Elective Surgery","Perioperative Care Outcomes in Older Adults",[301,302,303,304,305,306],"Quality of Recovery","Patient Reported Outcome Measure","Enhanced Recovery After Surgery","Health Care Quality","Postoperative Care","Older adults","2026-03-26",{"date":309,"type":37},"2026-04-01",{"date":311,"type":37},"2024-03-04",{"date":313,"type":21},"2027-09",{"name":43,"class":44},{"id":316,"slug":317,"hasResults":12,"nctId":318,"briefTitle":319,"officialTitle":320,"acronym":321,"eligibilityCriteria":322,"healthyVolunteers":12,"sex":53,"minAge":4,"maxAge":4,"enrollmentInfo":323,"targetDuration":4,"studyType":22,"phases":325,"briefSummary":326,"conditions":327,"keywords":330,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":332,"lastUpdatePostDateStruct":333,"startDateStruct":334,"completionDateStruct":336,"leadSponsor":338,"locationsCount":72},"100631395","nora-home-an-ambulatory-multimodal-monitoring-model-in-patients-with-minor-stroke-and-transient-ischemic-attacks-100631395","NCT07500116","NORA-HOME: An Ambulatory Multimodal Monitoring Model In Patients With Minor Stroke And Transient Ischemic Attacks","NORA-HOME. Efficiency And Safety An Ambulatory Multimodal Monitoring Model In Patients With Minor Stroke And Transient Ischemic Attacks","NORAHOME","Inclusion Criteria: Patients presenting to the Emergency Department with symptoms of TIA (complete recovery of neurological deficits within \\\u003C24 hours) or minor stroke (NIHSS ≤ 5)\n\n* Age \\>18 years.\n* Availability of a smartphone for the patient or caregiver.\n* Family support and\u002For formal caregiver.\n* Clinical stability during the last 12 hours in the Emergency Department.\n* Signed informed consent by the patient and\u002For family member or legal representative.\n\nExclusion Criteria:\n\n* Severe stenosis or symptomatic arterial occlusion requiring admission for potential reperfusion and\u002For arterial revascularization treatments.\n* Patients with pre-existing neurological or psychiatric conditions that may interfere with or complicate follow-up and evaluations.\n* Clinical (terminal condition) or social (language barrier) impossibility to complete follow-up assessments.",{"count":324,"type":21},250,[58],"In this project, we aim to validate a Home Hospitalization plan for patients with TIA or minor stroke. Our hypothesis is that our Multimodal Home Hospitalization program (NORAHOME) for patients with TIA and minor stroke is safe, reduces the complications associated with conventional hospitalization, and is more efficient than Standard Clinical Practice. To conduct the study, we require the voluntary participation of patients with TIA and minor strokes.",[328,329],"Stroke (CVA) or TIA","Stroke Recurrence",[331],"Stroke, TIA, Hospitalization at Home, Stroke Care, PROMs, PREMs","2026-03-25",{"date":276,"type":37},{"date":335,"type":37},"2025-01-29",{"date":337,"type":21},"2027-06-29",{"name":43,"class":44},{"id":340,"slug":341,"hasResults":12,"nctId":342,"briefTitle":343,"officialTitle":343,"acronym":4,"eligibilityCriteria":344,"healthyVolunteers":12,"sex":53,"minAge":4,"maxAge":4,"enrollmentInfo":345,"targetDuration":346,"studyType":124,"phases":4,"briefSummary":347,"conditions":348,"keywords":365,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":368,"lastUpdatePostDateStruct":369,"startDateStruct":371,"completionDateStruct":373,"leadSponsor":375,"locationsCount":72},"100630525","natural-history-study-for-patients-with-nemaline-myopathy-in-spain-100630525","NCT07488806","Natural History Study for Patients With Nemaline Myopathy in Spain","Inclusion Criteria:\n\n* Patients with a confirmed clinical and genetic diagnosis of MN (mutations in ACTA1, NEB, TPM2, TPM3, KBTBD13, CFL2, KLHL40, KLHL41, LMOD3, MYPN, TNNT1, TNNT3), or under discussion if they only have a compatible biopsy.\n* Signed informed consent by the patient or Legal Authority Responsible, and\u002For assent by the subject (in pediatric population).",{"count":217,"type":21},"5 Years","The objective of this natural history study is to comprehensively characterize the disease progression and clinical features of nemaline myopathies. The study aims to establish a well-defined cohort of patients in Spain, enabling long-term follow-up and facilitating recruitment for future clinical trials.",[349,350,351,352,353,354,355,356,357,358,359,360,361,362,363,364],"Nemaline Myopathy","Myopathies","Myopathic Conditions","NEB","ACTA1","TPM2","TPM3","TNNT1","CFL2","KBTBD13","KLHL40","KLHL41","LMOD3","Cohort Studies","MYPN","TNNT3",[366,367],"NATURAL HISTORY","NEMALINE MYOPATHY","2026-03-18",{"date":370,"type":37},"2026-03-23",{"date":372,"type":21},"2026-06",{"date":374,"type":21},"2032-06",{"name":43,"class":44},{"id":377,"slug":378,"hasResults":12,"nctId":379,"briefTitle":380,"officialTitle":380,"acronym":381,"eligibilityCriteria":382,"healthyVolunteers":12,"sex":53,"minAge":18,"maxAge":4,"enrollmentInfo":383,"targetDuration":4,"studyType":22,"phases":384,"briefSummary":385,"conditions":386,"keywords":389,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":391,"lastUpdatePostDateStruct":392,"startDateStruct":394,"completionDateStruct":395,"leadSponsor":397,"locationsCount":72},"100628026","evaluation-of-the-non-invasive-electrocardiographic-monitoring-strategy-associated-with-early-discharge-in-patients-with-conduction-disorder-through-tavi-implantation-100628026","NCT07456280","Evaluation of the Non-invasive Electrocardiographic Monitoring Strategy Associated With Early Discharge in Patients With Conduction Disorder Through TAVI Implantation","IMPROVE","Inclusion Criteria:\n\nAll inclusion criteria must be met\n\n* Age ≥ 18 years and\n* Undergone successful transfemoral or transaortic TAVI for severe aortic stenosis and\n* Presence of at least one of the following conduction disorders and\n* Pre-procedural basal conduction disorder (e.g., right\u002Fleft bundle branch block, bifascicular block, IVCD) with QRS between 120-160 msec.\n* De novo conduction disorder after TAVI (de novo bundle branch block) with QRS between 120-160 msec.\n* Clinical stability at 24 hours post-procedure and\n* Capacity to give informed consent.\n\nExclusion Criteria:\n\nNo exclusion criteria must be met\n\n* Immediate indication for permanent pacemaker following the procedure.\n* Persistent complete atrioventricular block.\n* QRS \\>160 msec and\u002For PR prolongation.\n* Haemodynamic instability or complications of TAVI (major bleeding, stroke, decompensated heart failure) that contraindicate early discharge.\n* Technical or clinical impossibility of using the PhysioMem PM 1004G monitoring system.\n* Life expectancy \\\u003C 12 months due to non-cardiovascular comorbidity.\n* Refusal or inability to undergo outpatient follow-up.\n* Pregnant or breastfeeding.",{"count":217,"type":21},[58],"Study to evaluate the efficacy and safety of a non-invasive electrocardiographic monitoring strategy associated with early discharge in patients with conduction disorder after transfemoral TAVI implantation, and its potential benefits compared to standard care.",[387,388],"Severe Aortic Valve Stenosis","Cardiovascular Diseases",[390],"TAVI(Transcatheter Aortic Valve Implantation)","2026-03-04",{"date":393,"type":37},"2026-03-06",{"date":309,"type":21},{"date":396,"type":21},"2028-08-01",{"name":43,"class":44},{"id":399,"slug":400,"hasResults":12,"nctId":401,"briefTitle":402,"officialTitle":403,"acronym":4,"eligibilityCriteria":404,"healthyVolunteers":12,"sex":53,"minAge":18,"maxAge":405,"enrollmentInfo":406,"targetDuration":4,"studyType":22,"phases":408,"briefSummary":409,"conditions":410,"keywords":415,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":421,"lastUpdatePostDateStruct":422,"startDateStruct":424,"completionDateStruct":426,"leadSponsor":428,"locationsCount":72},"100625429","virtual-reality-based-mindfulness-as-an-adjunct-to-treatment-as-usual-in-treatment-resistant-depression-100625429","NCT07422519","Virtual Reality-Based Mindfulness as an Adjunct to Treatment as Usual in Treatment-Resistant Depression","A Pilot Randomised Controlled Study Evaluating the Efficacy and Tolerability of Virtual Reality-Based Mindfulness as an Adjunct to Treatment as Usual in Treatment-Resistant Depression","Inclusion Criteria:\n\n* Age between 18 and 74 years, inclusive\n* Diagnosis of treatment-resistant Major Depressive Disorder (MDD), single or recurrent episode, in accordance with DSM-5 diagnostic criteria.\n* Inadequate response to two or more oral antidepressants during the current depressive episode\n* Inadequate response to at least one pharmacological combination or augmentation strategy\n* Ability and willingness to provide written informed consent for participation and data collection\n\nExclusion Criteria:\n\n* Presence of any contraindication to esketamine administration according to the approved product label\n* Current participation in another interventional clinical study involving antidepressant medication\n* Any medical, psychiatric, or other condition that, in the opinion of the investigator, could: (a) compromise participant safety or well-being, or (b) interfere with, limit, or confound study assessments or outcomes","74 Years",{"count":407,"type":21},30,[58],"The primary aim of this study is to evaluate the efficacy and tolerability of a combined Virtual Reality (VR)-based mindfulness intervention and pharmacological treatment compared with pharmacological treatment alone in reducing depressive symptoms in patients with Treatment-Resistant Depression (TRD).\n\nSecondary questions this study aims to address include:\n\n1. Does the combined intervention lead to changes in inflammatory blood parameters compared with pharmacological treatment alone?\n2. Does the addition of a VR-based mindfulness intervention prolong remission of depressive symptoms six months after treatment completion?\n3. Is the combined treatment with mindfulness and esketamine well-tolerated, and how does its adverse effect profile compare with esketamine treatment alone?\n4. Is there an association between changes in mindfulness trait levels, assessed using the FFMQ-SF, and reductions in depressive symptom severity?\n\nParticipants will be recruited from a Treatment-Resistant Depression Programme and randomly assigned to receive either VR-based mindfulness intervention in addition to treatment as usual or treatment as usual alone. The mindfulness intervention will last one month and include a total of 8 sessions. All participants will undergo comprehensive assessments at baseline and at predefined follow-up time points to evaluate clinical outcomes, inflammatory markers, tolerability, and remission duration.",[411,412,413,414],"Depression - Major Depressive Disorder","Depression Disorder","Depression Chronic","Treatment-Resistant Major Depressive Disorder",[416,417,418,419,420],"Treatment-Resistant Depression","Major Depressive Disorder","Mindfulness-Based Intervention","Virtual Reality","Esketamine","2026-02-25",{"date":423,"type":37},"2026-02-27",{"date":425,"type":37},"2025-09-18",{"date":427,"type":21},"2026-12-15",{"name":43,"class":44},{"id":430,"slug":431,"hasResults":12,"nctId":432,"briefTitle":433,"officialTitle":434,"acronym":435,"eligibilityCriteria":436,"healthyVolunteers":437,"sex":53,"minAge":18,"maxAge":4,"enrollmentInfo":438,"targetDuration":4,"studyType":124,"phases":4,"briefSummary":440,"conditions":441,"keywords":443,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":447,"lastUpdatePostDateStruct":448,"startDateStruct":450,"completionDateStruct":452,"leadSponsor":454,"locationsCount":72},"100626043","using-digital-twin-technology-and-clinical-decision-support-systems-to-improve-the-early-detection-personalised-treatment-and-long-term-monitoring-of-patients-across-the-full-spectrum-of-metabolic-associated-fatty-liver-disease-mafld-100626043","NCT07430501","Using Digital Twin Technology and Clinical Decision Support Systems to Improve the Early Detection, Personalised Treatment, and Long-term Monitoring of Patients Across the Full Spectrum of Metabolic-associated Fatty Liver Disease (MAFLD).","AcceleRating the Translation of Virtual Twins Towards a pErsonalised Management of Steatotic Liver Patients","ARTEMIS","INCLUSION CRITERIA:\n\n1. \\- Clinical Use Case 1: Liver disease staging in MASLD patients - Prediction model of fibrosis changes (progression and regression), with ability to distinguish between fast and non-fast fibrosis progression among MASLD patients.\n\n   * Age ≥18 years\n   * Diagnosis of MASLD confirmed by radiological imaging (any type: MR, CT, PET, VCTE, US, USE...) or histology (gold standard, following MASH SAF score)\n   * With at least one follow-up of minimum 1 year after diagnosis of MASLD, with radiological imaging or histology\n2. \\- Clinical Use case 2: MASLD and progression of cardiovascular diseases\n\n   * Age ≥18 years MASLD patients regardless of disease stage of severity (from simple steatosis to cirrhosis)\n   * Patients without known heart disease\n   * Cardiovascular assessment available\n\n3.1- Clinical Use case 3-TIPS: Patients with cirrhosis and portal hypertension who receive TIPS placement.\n\n* Age ≥18 years\n* TIPS indication (Baveno VII), except pre-emptive and salvage TIPS.\n* Recurrent variceal bleeding after failure of the usual pharmacological and endoscopic methods\n* Refractory or recurrent ascites or difficult to treat\n* Refractory Hydrothorax\n* Patients with diagnosis of liver cirrhosis (based on laboratory parameters, clinical, endoscopic, radiological or histological findings), of any aetiology.\n\n3.2.- Clinical Use Case 3-LT: Patients with cirrhosis and portal hypertension who received liver transplantation.\n\n* Age ≥18 years\n* All patients with cirrhosis (all aetiologies) who were transplanted\n\n  4.- Clinical Use Case 4: Prediction of cardiac complications due to HCC treatments\\* (\\*Note: includes surgical interventions, ablation, TACE, TARE, SIRT and immunotherapies)\n* Age ≥18 years\n* Diagnosis of HCC (any aetiology)\n* Cross sectional imaging follow-up (any modality) of liver diseases 6 months after treatment\n* Non-cirrhotic or no more than Child-Pugh B cirrhosis.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Patients without history of prior HCC\n* Patients with a history of hypertension should be well controlled (\\\u003C 140\u002F90 mmHg) on a regimen of antihypertensive therapy.\n* With a minimum follow-up of two years or until death, after diagnosis of HCC\n\n  5.- Other populations (participation in control arms)\n* Age ≥18 years\n* Subjects presenting cardiac fibrosis, without a known MASLD diagnosis (as controls for use case 2)\n\nEXCLUSION CRITERIA:\n\n1. \\- Clinical Use Case 1: Liver disease staging in MASLD patients - Prediction model of fibrosis changes (progression and regression), with ability to distinguish between fast and non-fast fibrosis progression among MASLD patients.\n\n   * Missing data on blood glucose, BMI and metabolic status.\n   * Patients who have received systemic chemotherapy\n   * Patients with hepatitis B (HBV) and hepatitis C (HCV), alcoholic liver disease (more than 5 years of drinking history, equivalent to alcohol volume ≥ 30g \u002F D in male and ≥ 20g \u002F D in female), drug-induced liver disease or autoimmune hepatitis.\n   * Subjects having a significant risk of bleeding (platelet \\\u003C 50x109 \u002F L, prothrombin activity \\\u003C 50%)\n   * Presence of any other form of chronic liver, at the time of MASLD diagnosis.\n2. \\- Clinical Use case 2: MASLD and progression of cardiovascular diseases\n\n   * Association with another cause of liver disease\n   * History of hepatitis B or C\n   * Already known coronary artery disease\n   * History of cardiovascular events\n\n3.1- Clinical Use case 3-TIPS: Patients with cirrhosis and portal hypertension who receive TIPS placement.\n\n* Non-cirrhosis TIPS\n* Portosinusoidal vascular disease\n* Complete portal vein thrombosis\n* Patients with surgical porto-caval shunts.\n* Patients with evidence of current locally advanced or metastatic malignancy\n* Patients with acute or chronic heart failure (New York Heart Association \\[NYHA\\]).\n* Patients with chronic obstructive pulmonary disease GOLD grade III\u002FIV\n* Patients with chronic kidney disease requiring renal replacement therapy\n* Patients with a known infection with human immunodeficiency virus (HIV) or have clinical signs and symptoms consistent with current HIV infection\n* Patients with previous liver transplantation\n* Patients lost to follow-up and therefore have an incomplete 1-year follow-up\n\n3.2.- Clinical Use Case 3-LT: Patients with cirrhosis and portal hypertension who received liver transplantation.\n\n* Patients who were transplanted due to acute liver failure.\n* Patients who were already transplanted before (retransplant)\n* Patients who are lost to follow-up in the first 5 years after liver transplant.\n\n  4.- Clinical Use Case 4: Prediction of cardiac complications due to HCC treatments\\* (\\*Note: includes surgical interventions, ablation, TACE, TARE, SIRT and immunotherapies)\n* Mixed-tumor HCC based on radiological and\u002For pathological examination\n* Uncontrolled inter-current illness or psychiatric illness or social situations that would limit compliance with study requirements.\n* Subjects with history of another primary cancer\n* Fully recovered from any prior surgery and\u002For radiation and none within 2 weeks of initiating treatment.\n* Subjects with active hepatitis B or C on antiviral compounds may remain on such treatment, except for interferon.\n* Subjects with diagnosis of tumor of mixed origin, either from radiological or biopsy report.\n\n  5.- Other populations (participation in control arms)\n* Patients with diagnosis of MASLD",true,{"count":439,"type":21},7720,"The goal of this observational study is to create a detailed virtual model to better understand how Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) develops. This model will also help predict heart problem at different stage of the disease.",[442],"Metabolic Dysfunction-Associated Steatotic Liver Disease",[444,445,446],"MASLD","Virtual twins","fatty liver patients","2026-02-17",{"date":449,"type":37},"2026-02-24",{"date":451,"type":21},"2026-02-23",{"date":453,"type":21},"2027-09-02",{"name":43,"class":44},{"id":456,"slug":457,"hasResults":12,"nctId":458,"briefTitle":459,"officialTitle":460,"acronym":4,"eligibilityCriteria":461,"healthyVolunteers":12,"sex":53,"minAge":462,"maxAge":463,"enrollmentInfo":464,"targetDuration":4,"studyType":22,"phases":465,"briefSummary":466,"conditions":467,"keywords":469,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":473,"lastUpdatePostDateStruct":474,"startDateStruct":476,"completionDateStruct":478,"leadSponsor":480,"locationsCount":72},"100611465","spanish-validation-of-a-psychosocial-needs-assessment-for-adolescents-and-young-adults-with-cancer-aya-post-100611465","NCT07240935","Spanish Validation of a Psychosocial Needs Assessment for Adolescents and Young Adults With Cancer (AYA-POST)","Validation of the Spanish Version of a Psychosocial Needs Assessment Questionnaire for Adolescents and Young Adults With Cancer (AYA-POST)","Inclusion Criteria:\n\n* Patients between 15 and 25 years old who provide informed consent (\\> 18 yo) or parents informed consent and patient consent in case of minors (15 to 18 yo)\n* Diagnosis of cancer (malignant solid tumor or hematologic malignancy) within 6 months prior to study inclusion or whose first non-surgical treatment (chemotherapy, radiotherapy, or targeted therapy) started within the last 6 months.\n* Treated from diagnosis or first non-surgical treatment at centers where the study is open.\n\nExclusion Criteria:\n\n* Patients who are not receiving their first line of non-surgical treatment.\n* Patients who do not have good understanding of Spanish (language used for the screening tool and questionnaires).\n* Patients with severe neurological impairment or other conditions that, in the investigator's opinion, prevent proper completion of study procedures.","15 Years","25 Years",{"count":217,"type":21},[58],"This prospective multicenter study aims to validate the Spanish version of the Distress Thermometer and accompanying list of psychosocial needs specifically adapted for adolescents and young adults (AYA) aged 15 to 25 who are diagnosed with cancer.\n\nThese tools, firstly developed by the National Comprehensive Cancer Network (NCCN) and then specifically adapted for AYA by Canteen Australia and validated in English-speaking countries, are widely used around the world to quickly identify emotional distress and unmet practical or social needs in cancer patients, helpting to detect their emotional distress and support needs, which can differ significantly from those of children or older adults.\n\nBy validating these screening tools in Spanish this study seeks to confirm whether they can reliably identify young patients who may be experiencing psychosocial difficulties.\n\nOnce validated, these tools can be easily integrated into clinical practice in Spanish-speaking countries, helping healthcare teams quickly identify vulnerable young patients, respond to their emotional needs earlier, and improve the overall quality of care.\n\nThe results will also highlight which psychosocial needs are most common in AYA cancer patients, supporting the development of future programs and services tailored to this population.",[468],"AYA Cancer Patients",[470,471,472],"AYA cancer psychosocial","AYA cancer Distress Thermometer","AYA cancer psychosocial needs","2026-01-19",{"date":475,"type":37},"2026-01-21",{"date":477,"type":37},"2025-10-10",{"date":479,"type":21},"2032-10-31",{"name":43,"class":44},{"id":482,"slug":483,"hasResults":12,"nctId":484,"briefTitle":485,"officialTitle":486,"acronym":4,"eligibilityCriteria":487,"healthyVolunteers":12,"sex":53,"minAge":18,"maxAge":4,"enrollmentInfo":488,"targetDuration":4,"studyType":124,"phases":4,"briefSummary":490,"conditions":491,"keywords":496,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":511,"lastUpdatePostDateStruct":512,"startDateStruct":514,"completionDateStruct":516,"leadSponsor":518,"locationsCount":72},"100617468","ai-assisted-transcranial-duplex-sonography-for-early-detection-of-intracerebral-haemorrhage-hyper-ai-scan-100617468","NCT07319013","AI-assisted Transcranial Duplex Sonography for Early Detection of Intracerebral Haemorrhage: HYPER-AI-SCAN","HYPER-AI-SCAN: HYPER-acute AI-assisted Sonographic Cerebral Hemorrhage Assessment Network","Inclusion Criteria:\n\n* Adult patients (age ≥18 years).\n* Clinical diagnosis of acute stroke (ischemic or intracerebral hemorrhage).\n* Able to undergo transtemporal transcranial ultrasound according to the standardized protocol (no clinical instability)\n* Informed consent obtained from the patient or legally authorized representative, per local regulations.\n\nExclusion Criteria:\n\n* Infratentorial hemorrhage (e.g., cerebellar or brainstem hemorrhage), due to limitations of transtemporal insonation.\n* Isolated subarachnoid hemorrhage without parenchymal involvement.\n* Hemodynamic instability or medical conditions requiring immediate life-saving intervention that preclude safe ultrasound recording.\n* Known skull defects or prior craniectomy on the side required for contralateral insonation.\n* Any condition that, in the opinion of the investigators, would interfere with protocol adherence or data accuracy.",{"count":489,"type":21},500,"The goal of this observational study is to evaluate whether transcranial Doppler ultrasound, combined with artificial intelligence (AI), can help identify intracerebral haemorrhage (ICH) in people with acute stroke (both men and women, adults of all ages) within 48 hours of symptom onset.\n\nThe main questions it aims to answer are:\n\nIs it feasible to perform standardized protocol transcranial ultrasound in acute stroke patients? Can AI models trained on ultrasound images accurately distinguish haemorrhagic stroke (\"ICH suspected\") from non-haemorrhagic stroke? There is no comparison group, because all participants will undergo both CT (as standard care) and ultrasound (research imaging), and the AI models will compare their ultrasound-based predictions against CT-confirmed diagnoses.\n\nParticipants will:\n\nundergo a non-invasive transcranial ultrasound scan after CT confirms the type of stroke allow researchers to collect coded ultrasound images for AI model training provide clinical and imaging information (already collected as part of routine care) to help evaluate factors related to diagnostic accuracy No treatments or changes to clinical care will be introduced as part of the study.",[492,493,494,495],"Stroke","Intracerebral Hemorrhage","Intracerebral Hemorrhage Basal Ganglia","Intracerebral Haemorrhage",[497,498,499,500,501,502,503,504,505,506,507,508,509,510],"stroke","intracerebral hemorrage","Ischemic Stroke","Hemorrhagic Stroke","transcranial ultrasound","Transcranial Doppler","Portable Ultrasound","Neurosonology","Artificial Intelligence","Machine Learning","Diagnostic Accuracy","Prehospital Care","Feasibility Study","Deep Learning","2025-12-19",{"date":513,"type":37},"2026-01-06",{"date":515,"type":37},"2025-03-14",{"date":517,"type":21},"2027-06",{"name":43,"class":44},{"id":520,"slug":521,"hasResults":12,"nctId":522,"briefTitle":523,"officialTitle":524,"acronym":525,"eligibilityCriteria":526,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":527,"targetDuration":4,"studyType":22,"phases":529,"briefSummary":530,"conditions":531,"keywords":532,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":536,"lastUpdatePostDateStruct":537,"startDateStruct":539,"completionDateStruct":540,"leadSponsor":542,"locationsCount":543},"100607832","nope37-angiogenic-factors-for-managing-term-preeclampsia-100607832","NCT07193680","NOPE37: Angiogenic Factors for Managing Term Preeclampsia","Angiogenic Markers for Confirming Term Preeclampsia (noPE-37 Trial): An Open-Label, Randomized Controlled Trial","NOPE37","Inclusion Criteria:\n\n* Age ≥18 years\n* Singleton pregnancy\n* Preeclampsia without severe features according to the ACOG definition\n* Antegrade diastolic flow in the umbilical artery Doppler\n* Gestational age between 36+0 and 38+6 weeks of gestation\n* Gestational age confirmed by fetal crown-rump length measurement in the first-trimester scan (from 11+0 to 13+6 weeks of gestation) or by in vitro fertilization dates\n\nExclusion Criteria:\n\n* Fetal death\n* Preeclampsia with severe features according to the ACOG definition, eclampsia, or any condition that requires immediate delivery\n* Absent or reversed end-diastolic flow in the umbilical artery Doppler\n* Non-reassuring CTG\n* Decreased fetal movements\n* Biophysical profile score ≤6\n* Oligohydramnios\n* Refusal to provide informed consent\n* Fetal malformation\n* Placental abruption\n* Antiphospholipid antibody syndrome",{"count":528,"type":21},750,[58],"This study tests the hypothesis that, in women with preeclampsia without severe features, delivery management based on sFlt-1\u002FPlGF would reduce the rate of induction of labor without worsening the rate of progression to preeclampsia with severe features and other maternal complications.",[27],[533,534,535],"preeclampsia","angiogenic factors","expectant management","2025-12-04",{"date":538,"type":37},"2025-12-11",{"date":536,"type":37},{"date":541,"type":21},"2028-04",{"name":43,"class":44},23,{"id":545,"slug":546,"hasResults":12,"nctId":547,"briefTitle":548,"officialTitle":549,"acronym":550,"eligibilityCriteria":551,"healthyVolunteers":12,"sex":53,"minAge":18,"maxAge":4,"enrollmentInfo":552,"targetDuration":4,"studyType":124,"phases":4,"briefSummary":554,"conditions":555,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":559,"lastUpdatePostDateStruct":560,"startDateStruct":562,"completionDateStruct":564,"leadSponsor":566,"locationsCount":72},"100614616","early-biological-and-mechanical-profiling-in-sepsis-associated-ards-100614616","NCT07281911","Early Biological and Mechanical Profiling in Sepsis-Associated ARDS","Characterization of Early Biological and Mechanical Profiles in Sepsis-Associated ARDS for Studying Compartamentalization (Serial Bronchoalveolar Lavage and Plasma Biomarkers) to Identify Inflammatory and Hybrid Subphenotypes","EARLY-SARDS","Inclusion Criteria:\n\n* Age ≥18\n* ARDS diagnosis per Berlin definition\n* Sepsis per Sepsis-3 criteria\n* Invasive mechanical ventilation\n* Expected to remain intubated ≥72 hours\n* Consent from surrogate\n\nExclusion Criteria:\n\n* Contraindications to bronchoscopy\u002FBAL\n* Refractory hemodynamic instability\n* Pregnancy\n* Pulmonary transplant patients\n* Surrogate declines participation",{"count":553,"type":21},180,"Sepsis-associated acute respiratory distress syndrome (ARDS) is one of the deadliest and most biologically heterogeneous forms of respiratory failure. Despite uniform diagnostic criteria, patients with septic ARDS show wide variability in inflammatory intensity, alveolar epithelial and endothelial injury, alveolar fluid composition, ventilatory mechanical properties, and clinical evolution. Early identification of these differences may enable better prognostication and more precise treatment.\n\nThis prospective observational study aims to deeply characterize the earliest phases of septic ARDS by integrating serial bronchoalveolar lavage (BAL) at 0, 24 and 72 hours with parallel plasma biomarker profiling and detailed mechanical ventilation data. This design captures the evolving biological and physiological landscape of septic ARDS during its most dynamic window. The central goal is to identify systemic, alveolar, and hybrid bio-mechano-inflammatory subphenotypes that can inform personalized approaches to support, risk stratification, and future interventional trials.",[556,557,558],"Acute Hypoxemic Respiratory Failure","Sepsis","ARDS (Acute Respiratory Distress Syndrome)","2025-12-02",{"date":561,"type":37},"2025-12-15",{"date":563,"type":21},"2026-03-01",{"date":565,"type":21},"2027-11-01",{"name":43,"class":44},{"id":568,"slug":569,"hasResults":12,"nctId":570,"briefTitle":571,"officialTitle":572,"acronym":573,"eligibilityCriteria":574,"healthyVolunteers":12,"sex":53,"minAge":18,"maxAge":4,"enrollmentInfo":575,"targetDuration":4,"studyType":22,"phases":577,"briefSummary":578,"conditions":579,"keywords":580,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":587,"lastUpdatePostDateStruct":588,"startDateStruct":590,"completionDateStruct":592,"leadSponsor":594,"locationsCount":72},"100611466","functional-improvement-in-subacutechronic-stroke-through-non-invasive-virtual-reality-based-telerehabilitation-100611466","NCT07240948","Functional Improvement in Subacute\u002FChronic Stroke Through Non-invasive Virtual-reality-Based Telerehabilitation","Functional Improvement in Subacute\u002FChronic Stroke Patients Through a Non-invasive Virtual-reality Based Telerehabilitation Home System","MUVITY","Inclusion Criteria:\n\n* Age \\>18 years-old\n* Ischemic or hemorrhagic stroke within 3 to 12 months before inclusion\n* Inclusion modified Rankin scale 1 to 3\n* Motor rehabilitation requirements defined by the stroke neurologist\u002Fphysiatrist in the out-patient clinic\n* Bipedal standing: capable of keeping on two feet for two minutes without using hand supports.\n\nExclusion Criteria:\n\n* Technological abilities: patient and caregiver do not manage smartphone and computer\n* Severe aphasia\u002F language barrier with patient\u002Fcaregiver that impairs communication\n* Severe cognitive impairment (dementia) that affects short- and medium-term memory.\n* End-of-life- or life-threatening pathology with an estimated survival \\\u003C1 year.\n* Receiving intense physical therapy (rehabilitation with at least one face-to-face physical treatment\u002Fweek).",{"count":576,"type":21},322,[58],"Stroke is the leading cause of disability in adults worldwide. Rehabilitation after a stroke is crucial, even after the acute phase: initially, it aims to recover the deficits caused by the stroke, but in the subacute\u002Fchronic phases the objective is to maintain the functional abilities already acquired. After the acute phase, traditional rehabilitation methods usually include exercises prescribed by a therapist that the patient performs on their own. However, their effectiveness is limited due to the lack of supervision, adherence, and insufficient information provided to the patient about their progress, which would require regular in-person contact with the patient. To date, public health systems have been unable to provide this kind of access to rehabilitation for post-stroke patients, with the risk of worsening deficits and a decline in quality of life. We plan to develop an individualized home-based monitoring program enhanced by telerehabilitation based on non-immersive virtual reality (without the need for VR goggles or other \"gadgets\") (MUVITY) for patients who suffered a stroke in the subacute\u002Fchronic phase.\n\nPatients seen during an outpatient consultation who require rehabilitation will be randomly assigned either the usual treatment (they will receive a document describing the exercises to perform and a suggested schedule, togheter with an app for communication and health-education, Nora) or the MUVITY treatment: patients will be provided with the telerehabilitation system using a computer and camera where they will perform the rehabilitation exercises, which will be individually adapted according to their progress by a physiotherapist, together with Nora. We believe that MUVITY will lead to improved motor function, emotional well-being, and quality of life, increasing adherence to rehabilitation treatment compared with usual care, and that it can be used in terms of patient satisfaction and pain levels.\n\nOur findings could confirm that telerehabilitation improves motor function and quality of life after stroke. Furthermore, since it is a home-based system, its use would considerably increase the number of patients who can receive treatment compared with in-person therapies, eliminating geographic barriers related to distance from rehabilitation centers and offering cost-effective access to effective treatment for all patients. Additionally, our system allows continuous interaction between patients and healthcare professionals, and provides information about their progress, which helps reduce stress related to uncertainty about the future and supports key aspects of monitoring patients in the subacute\u002Fchronic phase of stroke such as risk factor control and early detection of complications.",[492],[581,582,583,584,585,586],"Stroke rehabilitation","chronic stroke rehabilitation","tele-rehabilitation","telestroke","telehealth","home rehabilitation","2025-11-16",{"date":589,"type":37},"2025-11-21",{"date":591,"type":21},"2025-11",{"date":593,"type":21},"2027-03",{"name":43,"class":44},{"id":596,"slug":597,"hasResults":12,"nctId":598,"briefTitle":599,"officialTitle":600,"acronym":4,"eligibilityCriteria":601,"healthyVolunteers":437,"sex":53,"minAge":18,"maxAge":292,"enrollmentInfo":602,"targetDuration":4,"studyType":22,"phases":603,"briefSummary":604,"conditions":605,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":609,"lastUpdatePostDateStruct":610,"startDateStruct":612,"completionDateStruct":614,"leadSponsor":616,"locationsCount":617},"100544505","visible-abdominal-distension-100544505","NCT06369753","Visible Abdominal Distension","Tratamiento de la distensión Abdominal Funcional","Inclusion Criteria:\n\n* episodes of visible abdominal distension triggered by meal ingestion\n\nExclusion Criteria:\n\n* organic cause detected by clinical work-up\n* constipation\n* abdominal distension not confirmed by the 7-day clinical questionnaires in the pre- intervention evaluation",{"count":217,"type":21},[58],"Background. Abdominal distention is produced by an abnormal somatic postural tone. The authors developed an original biofeedback technique. In a randomized, placebo-controlled trial the authors demonstrated the superiority of biofeedback over placebo for the treatment of abdominal distention. However, the technique is technically complex and unpractical.\n\nAim. To prove the efficacy of a noninstrumental biofeedback technique, transmitted by a standard training program, for the treatment of abdominal distension in different centers.\n\nSelection criteria. Episodes of visible abdominal distension. Intervention. Patients will be randomized into biofeedback and placebo groups. Three sessions of either biofeedback or placebo intervention will be performed during the first 3 weeks of the intervention period.\n\nBiofeedback: Patients will be taught to control abdominal and thoracic muscular activity by providing instructions using an original video support. In each center one operator will receive a standard training on how to deliver the noninstrumental biofeedback treatment. Patients will be instructed to perform the same exercises before and after breakfast, lunch and dinner during the 4-week intervention period.\n\nPlacebo: Sham measurements of abdominal and thoracic motion will be performed, and a pill of placebo containing 0.21 g glucose will be administered; patients will be instructed to take a pill of placebo before breakfast, lunch and dinner during the 4-week intervention period.",[606,607,608],"Irritable Bowel Syndrome","Dyspepsia","Functional Bloating","2025-10-30",{"date":611,"type":37},"2025-10-31",{"date":613,"type":37},"2025-07-30",{"date":615,"type":21},"2026-10",{"name":43,"class":44},7,{"id":619,"slug":620,"hasResults":12,"nctId":621,"briefTitle":622,"officialTitle":623,"acronym":624,"eligibilityCriteria":625,"healthyVolunteers":12,"sex":53,"minAge":4,"maxAge":4,"enrollmentInfo":626,"targetDuration":4,"studyType":124,"phases":4,"briefSummary":628,"conditions":629,"keywords":639,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":645,"lastUpdatePostDateStruct":646,"startDateStruct":648,"completionDateStruct":650,"leadSponsor":651,"locationsCount":652},"100608787","integrative-diagnosis-for-scd-and-other-rads-100608787","NCT07206095","Integrative Diagnosis for SCD and Other RADs","Integrative Diagnosis of Sickle Cell Disease (SCD) and Other Rare Anemia Disorders (RADs) for Personalized Medicine","INTEGRA","Inclusion Criteria:\n\n* Patients sustaining a confirmed or suspected diagnosis of an hereditary rare hemolytic anemia:\n* Sickle cell disease\n* Thalassemic syndromes\n* Congenital dyserythropoietic anemia\n* Enzymopathy\n* Unstable Hemoblogin \u002F Altered oxygen affinity\n* Hereditary stomatocytosis\n* Hereditary pyropoikilocytosis\n* Hereditary spherocytosis with severe anemia (\\\u003C8 g\u002FdL) or inconclusive diagnosis:\n* Patient with chronic hemolytic anemia and red cell smear compatible, but with:\n* EMA binding test: inconclusive or negative\n* Genetic testing: no definitive diagnosis (VUS or no findings)\n* Not transplanted or undergoing gene therapy at the time of inclusion. Patients with graft failure without a new transplant may be included.\n\nExclusion Criteria:\n\n* Carrier traits in autosomal recessive hereditary anemias",{"count":627,"type":21},200,"INTEGRA aims at enabling personalized medicine for RHADs patients by the establishment of an integrative diagnostic approach based on deep phenotypic and genetic characterization through combining new generation methodologies.",[630,631,632,633,634,635,636,637,638],"Sickle Cell Disease","Thalassaemia","Congenital Dyserythropoietic Anemia (CDA)","Enzyme Disorder; Anemia","Spherocytosis, Hereditary","Stomatocytosis","Hemoglobin Disorder","Anemia Due to Membrane Defect","Rare Anemia Disorders",[640,641,642,643,644],"SICKLE CELL DISEASE","RARE ANEMIA DISORDERS","PERSONALIZED MEDICINE","DIAGNOSIS","EKTACYTOMETRY","2025-09-25",{"date":647,"type":37},"2025-10-03",{"date":649,"type":37},"2020-11-13",{"date":41,"type":21},{"name":43,"class":44},9,{"id":654,"slug":655,"hasResults":12,"nctId":656,"briefTitle":657,"officialTitle":658,"acronym":659,"eligibilityCriteria":660,"healthyVolunteers":12,"sex":53,"minAge":18,"maxAge":661,"enrollmentInfo":662,"targetDuration":4,"studyType":22,"phases":664,"briefSummary":665,"conditions":666,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":668,"lastUpdatePostDateStruct":669,"startDateStruct":671,"completionDateStruct":673,"leadSponsor":675,"locationsCount":72},"100605918","the-effect-of-a-probiotic-administration-as-an-add-on-treatment-in-multiple-sclerosis-100605918","NCT07168772","The Effect of a Probiotic Administration as an add-on Treatment in Multiple Sclerosis","The Effect of a Probiotic Administration as an add-on Treatment in Multiple Sclerosis: a Randomized, Double-blind, Placebo-controlled Clinical Trial","PROBiMS","Inclusion Criteria:\n\n* Patients aged 18-55 years, inclusive\n* Diagnosis of RRMS (McDonald Criteria 2017 and Lublin phenotype classification 2014)\n* Expanded disability status scale (EDSS) score less than or equal to 5.5\n* Patients receiving a first line treatment with teriflunomide or dimethyl fumarate at a stable dose, for at least 24 weeks, or patients who are not receiving treatment because they do not want to receive a DMT after the investigator has informed them of their possible respective benefits and possible adverse events\n* At enrollment, the patient is not expected to require a change in DMT\n* Patients showing a maximum of two new lesions on MRI prior to inclusion\n* Females of childbearing potential must have a negative urine pregnancy test result prior to initiation of study product\n* For females of childbearing potential: agreement to use adequate contraceptive methods during the treatment period\n* Ability to comply with the study protocol\n* Patients must sign and date a written informed consent prior to entering the study\n\nExclusion Criteria:\n\n* Relapse the month before enrollment\n* Presence of a new lesion, indicative of radiological activity, on the MRI performed before starting the study\n* Use of corticosteroids the month before enrollment\n* Use of antibiotics three months before enrollment\n* Taking other forms of symbiotic, probiotic, prebiotic and postbiotic supplements three months before enrollment\n* Patients suffering from any type of bowel disease\n* Pregnant or breastfeeding or intending to become pregnant during the study.\n* Be menopausal\n* Be a smoker","55 Years",{"count":663,"type":21},80,[58],"It is a randomized, double-blind, placebo-controlled clinical trial whose general objective of this study is to determine the effects of probiotic administration in multiple sclerosis patients.\n\n80 patients with relapsing-remitting multiple sclerosis will be enrolled in the study. Patients will be randomly assigned to receive either a probiotic (n=40) or a placebo (n=40) stratified by type of medication, gender and use of hormonal contraceptive treatment. They will receive a probiotic (Lactibane Iki) or placebo sachet twice a day for six months.",[667],"Multiple Sclerosis","2025-09-22",{"date":670,"type":37},"2025-09-23",{"date":672,"type":37},"2025-07-10",{"date":674,"type":21},"2027-12-31",{"name":43,"class":44},{"id":677,"slug":678,"hasResults":12,"nctId":679,"briefTitle":680,"officialTitle":680,"acronym":681,"eligibilityCriteria":682,"healthyVolunteers":12,"sex":53,"minAge":18,"maxAge":4,"enrollmentInfo":683,"targetDuration":685,"studyType":124,"phases":4,"briefSummary":686,"conditions":687,"keywords":690,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":699,"lastUpdatePostDateStruct":700,"startDateStruct":702,"completionDateStruct":704,"leadSponsor":706,"locationsCount":707},"100605225","real-world-prospective-study-on-the-use-of-anti-cgrp-drugs-in-migraine-100605225","NCT07159750","Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine","EUREkA","Inclusion Criteria:\n\n* Migraine diagnosis according to ICHD-III.\n* Prescription of erenumab, galcanezumab, fremanezumab, eptinezumab, atogepant or rimegepant according to prescriptor criteria and reimbursement criteria according to local regulations.\n* Signature of informed consent.\n\nExclusion Criteria:\n\n* Presence of headache different from migraine.\n* Active severe psychiatric condition or cognitive impairment which may affect the ability to consent patient's participation in the study.",{"count":684,"type":21},700,"2 Years","The goal of this observational study is to evaluate clinical differences in patients who received preventive treatment with medication targeting calcitonin gene-related peptide (CGRP) or its receptor: monoclonal antibodies (erenumab, galcanezumab, fremanezumab, eptinezumab) or gepants (rimegepant, atogepant) during a 2-year period observation phase.",[249,688,689],"Episodic Migraine","Chronic Migraine, Headache",[249,691,692,688,693,694,695,696,697,698],"Prevention","Chronic Migraine","galcanezumab","erenumab","fremanezumab","eptinezumab","rimegepant","atogepant","2025-08-29",{"date":701,"type":37},"2025-09-08",{"date":703,"type":37},"2024-01-02",{"date":705,"type":21},"2026-01",{"name":43,"class":44},26,{"id":709,"slug":710,"hasResults":12,"nctId":711,"briefTitle":712,"officialTitle":713,"acronym":4,"eligibilityCriteria":714,"healthyVolunteers":12,"sex":53,"minAge":18,"maxAge":54,"enrollmentInfo":715,"targetDuration":4,"studyType":22,"phases":717,"briefSummary":718,"conditions":719,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":721,"lastUpdatePostDateStruct":722,"startDateStruct":724,"completionDateStruct":726,"leadSponsor":727,"locationsCount":72},"100590740","treatment-of-rumination-100590740","NCT06971354","Treatment of Rumination","Tratamiento de la rumiación: Estudio Aleatorizado, Paralelo y Controlado","Inclusion Criteria:\n\n* Rumination syndrome\n\nExclusion Criteria:\n\n* Relevant organic diseases",{"count":716,"type":21},40,[58],"Background: Rumination syndrome is characterized by the involuntary regurgitation of previously ingested food from the stomach to the mouth, triggered by an unintentional contraction of the abdominal muscles along with simultaneous relaxation of the esophageal sphincters. Based on this mechanism, a biofeedback technique targeting muscular activity has been developed and shown to be effective. However, such techniques are often complex and not widely accessible.\n\nHypothesis: Rumination can be effectively treated using a simplified, non-instrumental biofeedback technique based on cognitive intervention.\n\nObjective: To evaluate the effectiveness of a non-instrumental biofeedback technique incorporating cognitive intervention for the treatment of rumination. The methodology will build on prior studies, employing a more streamlined biofeedback approach.\n\nMethods: Participants will be assigned to parallel groups with balanced sex distribution. The study will compare responses to biofeedback versus a control intervention. Over a four-week period, each participant will undergo three treatment sessions:\n\nThe biofeedback group will be trained to control abdominothoracic musculature through cognitive intervention, supported by original visual materials, both before and after a standardized test meal.\n\nThe control group will receive a placebo capsule prior to the test meal, and regurgitation episodes will be recorded.\n\nFollowing the initial session, biofeedback participants will continue with daily exercises, while control participants will take a placebo with each meal. Treatment response will be assessed by comparing outcomes before and after the intervention. After post-treatment assessment, control group participants will be offered the opportunity to receive biofeedback therapy.\n\nRelevance: This project aims to determine the efficacy of a simplified mechanistic intervention for rumination. If successful, this approach could be adopted in additional healthcare settings.",[720],"Rumination Syndrome","2025-07-03",{"date":723,"type":37},"2025-07-09",{"date":725,"type":37},"2025-05-02",{"date":615,"type":21},{"name":43,"class":44},""]